Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 16;10(1):32.
doi: 10.1186/s13395-020-00243-4.

Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature

Tokunbor A Lawal  1 , Joshua J Todd  2 , Jessica W Witherspoon  2 , Carsten G Bönnemann  3 , James J Dowling  4 , Susan L Hamilton  5 , Katherine G Meilleur  2 , Robert T Dirksen  6
Affiliations
Review

Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature

Tokunbor A Lawal et al. Skelet Muscle. .

Abstract

The RYR1 gene, which encodes the sarcoplasmic reticulum calcium release channel or type 1 ryanodine receptor (RyR1) of skeletal muscle, was sequenced in 1988 and RYR1 variations that impair calcium homeostasis and increase susceptibility to malignant hyperthermia were first identified in 1991. Since then, RYR1-related myopathies (RYR1-RM) have been described as rare, histopathologically and clinically heterogeneous, and slowly progressive neuromuscular disorders. RYR1 variants can lead to dysfunctional RyR1-mediated calcium release, malignant hyperthermia susceptibility, elevated oxidative stress, deleterious post-translational modifications, and decreased RyR1 expression. RYR1-RM-affected individuals can present with delayed motor milestones, contractures, scoliosis, ophthalmoplegia, and respiratory insufficiency.Historically, RYR1-RM-affected individuals were diagnosed based on morphologic features observed in muscle biopsies including central cores, cores and rods, central nuclei, fiber type disproportion, and multi-minicores. However, these histopathologic features are not always specific to RYR1-RM and often change over time. As additional phenotypes were associated with RYR1 variations (including King-Denborough syndrome, exercise-induced rhabdomyolysis, lethal multiple pterygium syndrome, adult-onset distal myopathy, atypical periodic paralysis with or without myalgia, mild calf-predominant myopathy, and dusty core disease) the overlap among diagnostic categories is ever increasing. With the continuing emergence of new clinical subtypes along the RYR1 disease spectrum and reports of adult-onset phenotypes, nuanced nomenclatures have been reported (RYR1- [related, related congenital, congenital] myopathies). In this narrative review, we provide historical highlights of RYR1 research, accounts of the main diagnostic disease subtypes and propose RYR1-related disorders (RYR1-RD) as a unified nomenclature to describe this complex and evolving disease spectrum.

Keywords: Clinical neurology; History; Ion channel defects; Myopathy; Neuromuscular disease; Skeletal muscle.

PubMed Disclaimer

Conflict of interest statement

Dr. Lawal has received support from the RYR-1 Foundation.

Dr. Todd has received support from the RYR-1 Foundation.

Dr. Witherspoon has received support from the RYR-1 Foundation.

Dr. Dirksen is a member of scientific advisory board of the RYR-1 Foundation. Dr. Dirksen has received support from the RYR-1 Foundation, Muscular Dystrophy Association, and the NIH (AR053349).

Dr. Bönnemann is a member of scientific advisory board of the RYR-1 Foundation. Dr. Bönnemann has received funding from Cure CMD.

Dr. Dowling is a member of scientific advisory board of the RYR-1 Foundation and Denature, and a member of the scientific council of the Muscular Dystrophy Association. Dr. Dowling has received support from the RYR-1 Foundation and Muscular Dystrophy Association.

Dr. Hamilton is a member of scientific advisory board of the RYR-1 Foundation. Dr. Hamilton has received the following support from the NIH: R01AR072602, R01AR072475, and R01AR053349. Dr. Hamilton has also received a grant from the Muscular Dystrophy Association and a gift from the McNair Foundation.

Dr. Meilleur has received support from the RYR-1 Foundation.

Figures

Fig. 1
Fig. 1
Timeline of significant discoveries/milestones in the evolution of RYR1-RD. 1900s to present: In the twentieth century, congenital myopathy diagnoses were based primarily on muscle biopsy histopathologic features. Advancements in next-generation sequencing enabled more precise identification of RYR1-related phenotypes. Solving of the RyR1 structure at near-atomic resolution provided valuable insight into RyR1 channel function and disease mechanisms. These advances paved the way for the first RYR1-RM clinical trial completed in 2018 and the Phase 1 Rycal trial which began enrolling participants in 2020
Fig. 2
Fig. 2
Overview of the RYR1 disease spectrum. At time of presentation, clinical severity can vary according to mode of inheritance (dominant, de novo, recessive), histopathologic features, and phenotypes ranging from severe neonatal onset to mild non-progressive muscle weakness. Recessive cases are typically more severe than dominant cases. The majority of histopathological features are associated with more severe clinical phenotypes, though this may not hold true for the core myopathies. Emerging clinical phenotypes associated with RYR1 variations also vary in severity
Fig. 3
Fig. 3
Distinct and overlapping features of the RYR1-RD spectrum. Individuals with RYR1-RD present with both myopathic and non-myopathic features. Histopathology can overlap among the different subtypes. Additionally, some phenotypes manifest following exposure to pharmacologic, physiologic, or environmental triggers. A classification system based on three distinct and overlapping categories (myopathic, non-myopathic, and triggered) accommodates current and most future subtypes of RYR1-RD
See this image and copyright information in PMC

Similar articles

  • Ryanodine Receptor 1-Related Myopathies: Diagnostic and Therapeutic Approaches.
    Lawal TA, Todd JJ, Meilleur KG. Lawal TA, et al. Neurotherapeutics. 2018 Oct;15(4):885-899. doi: 10.1007/s13311-018-00677-1. Neurotherapeutics. 2018. PMID: 30406384 Free PMC article. Review.
  • The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutations.
    Knuiman GJ, Küsters B, Eshuis L, Snoeck M, Lammens M, Heytens L, De Ridder W, Baets J, Scalco RS, Quinlivan R, Holton J, Bodi I, Wraige E, Radunovic A, von Landenberg C, Reimann J, Kamsteeg EJ, Sewry C, Jungbluth H, Voermans NC. Knuiman GJ, et al. J Neurol. 2019 Apr;266(4):876-887. doi: 10.1007/s00415-019-09209-z. Epub 2019 Feb 20. J Neurol. 2019. PMID: 30788618 Free PMC article.
  • Intracellular calcium leak as a therapeutic target for RYR1-related myopathies.
    Kushnir A, Todd JJ, Witherspoon JW, Yuan Q, Reiken S, Lin H, Munce RH, Wajsberg B, Melville Z, Clarke OB, Wedderburn-Pugh K, Wronska A, Razaqyar MS, Chrismer IC, Shelton MO, Mankodi A, Grunseich C, Tarnopolsky MA, Tanji K, Hirano M, Riazi S, Kraeva N, Voermans NC, Gruber A, Allen C, Meilleur KG, Marks AR. Kushnir A, et al. Acta Neuropathol. 2020 Jun;139(6):1089-1104. doi: 10.1007/s00401-020-02150-w. Epub 2020 Mar 31. Acta Neuropathol. 2020. PMID: 32236737 Free PMC article.
  • Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies.
    Zhou H, Jungbluth H, Sewry CA, Feng L, Bertini E, Bushby K, Straub V, Roper H, Rose MR, Brockington M, Kinali M, Manzur A, Robb S, Appleton R, Messina S, D'Amico A, Quinlivan R, Swash M, Müller CR, Brown S, Treves S, Muntoni F. Zhou H, et al. Brain. 2007 Aug;130(Pt 8):2024-36. doi: 10.1093/brain/awm096. Epub 2007 May 4. Brain. 2007. PMID: 17483490
  • Multi-minicore Disease.
    Jungbluth H. Jungbluth H. Orphanet J Rare Dis. 2007 Jul 13;2:31. doi: 10.1186/1750-1172-2-31. Orphanet J Rare Dis. 2007. PMID: 17631035 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dubowitz V. The “new” myopathies. Neuropediatrics. 1969;1(02):137–148. doi: 10.1055/s-0028-1091869. - DOI
    1. North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowling JJ, et al. Approach to the diagnosis of congenital myopathies. Neuromuscul Disord. 2014;24(2):97–116. doi: 10.1016/j.nmd.2013.11.003. - DOI - PMC - PubMed
    1. Witherspoon JW, Meilleur KG. Review of RyR1 pathway and associated pathomechanisms. Acta Neuropathol Commun. 2016;4(1):121. doi: 10.1186/s40478-016-0392-6. - DOI - PMC - PubMed
    1. Lai FA, Erickson HP, Rousseau E, Liu QY, Meissner G. Purification and reconstitution of the calcium release channel from skeletal muscle. Nature. 1988;331(6154):315–319. doi: 10.1038/331315a0. - DOI - PubMed
    1. Fujii J, Otsu K, Zorzato F, de Leon S, Khanna VK, Weiler JE, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science (New York, NY) 1991;253(5018):448–451. doi: 10.1126/science.1862346. - DOI - PubMed

Publication types

MeSH terms

Substances